Alzheon outlined plans for a major fundraising round despite a Phase 3 miss for its Alzheimer’s drug candidate. The company signaled it is pursuing up to $500 million to fund next steps as it reassesses its clinical strategy following the setback. For investors, the combination of a late-stage failure and an aggressive capital plan points to expectations that additional data, protocol adjustments, or pipeline alternatives could still unlock value. The fundraising announcement will likely refocus market attention on how Alzheon structures the turnaround—particularly which patient populations, endpoints, and development options it prioritizes going forward.